Table 1.
Baseline characteristics of S-TPI cases and those in SITS-UK and VISTA with mRS of ≤ 2 pre treatment
| S-TPI N = 2,131 | SITS-UK, N = 2,401 | VISTA untreated N = 4,630 | |||
|---|---|---|---|---|---|
| Characteristic | Cases omitted from analyses (n = 227) | Patients: surviving at 3-months (n = 1,996) | Patients: not surviving to 3-months (n = 405) | ||
| Age mean (SD) | 65.9 (11.4) | 67.8 (13.26) | 66.7 (12.7) | 73.3 (11.3) | 70.5 (12.2) |
| Sex, % male | 54.7 % | 58.6 % | 58.7 % | 56.5 % | 51.6 % |
| NIHSS score (median, IQR) | 12 (8,17) | 12 (7,18)b | 12 (8,17) | 19 (15,22) | 13 (8,18) |
| Hypertension % | 58.8 % | 60.36 % | 58.0 % | 62.5 % | 72.1 %a |
| Diabetes % | 20.8 % | 14.9 % | 12.0 % | 17.3 % | 21.4 % |
| Prior stroke % | 16.6 % | 14.41 % | 13.6 % | 14.8 % | 34.3 %a |
| Atrial fibrillation % | 18.6 % | 27.0 % | 23.6 % | 30.6 % | 31.6 % |
| Onset time to treatment (OTT) minutes (median, IQR) | 235 (155,290) | 146 (109,175) | 150 (120, 175) | 150 (120, 178) | - |
| OTT, % within 3–4.5 h | 61.3 % | 15.3 % | 16.6 % | 17.3 % | - |
| Systolic blood pressure, mm Hg (mean, SD) | 152.6 (20.3) | 145.5 (21.8)a | 146.9 (20.8) | 147.9 (21.0) | 156.8 (26.7) |
| Serum glucose mmol/l (median, IQR) | 6.78 (5.83,8.58) | 6.2 (5.6,7.8) | 6.2 (5.4, 7.5) | 6.9 (6.0, 8.4) | 6.7 (5.8,8.5) |
| Signs of current infarction on pre-treatment scan % | NA | 23.9 % | 24.3 % | 34.8 % | NA |
| Congestive heart failure % | 12.1 % | 4.5 % | 4.6 % | 6.9 % | NA |
aignoring missing values, bNational Institutes of Health Stroke Scale
S-TPI = Stroke-Thrombolytic Predictive Instrument
SITS-UK = Safe Implementation of Treatments in Stroke UK